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Osteosarcoma is a primary bone malignancy that typically occurs during adolescence but also has a second incidence peak
in the elderly. It occurs most commonly in the long bones, although there is variability in location between age groups. The
etiology of osteosarcoma is not well understood; it occurs at increased rates in individuals with Paget disease of bone, after
therapeutic radiation, and in certain cancer predisposition syndromes. It also occurs more commonly in taller individuals, but
a strong environmentalcomponentto osteosarcomarisk hasnot been identiﬁed. Severalstudies suggest thatosteosarcomamaybe
associated with single nucleotide polymorphisms in genes important in growth and tumor suppression but the studies are limited
by sample size. Herein, we review the epidemiology of osteosarcoma as well as its known and suspected risk factors in an eﬀort to
gain insight into its etiology.
1.Introduction
Osteosarcoma, the most common primary bone malignancy,
typically during the adolescent growth spurt but there
is a second, smaller peak in the elderly [1]. There are
a limited number of proven risk factors associated with
osteosarcoma. It occurs more frequently after therapeutic
radiation for a diﬀerent cancer, in individuals with certain
cancer predisposition syndromes, and in those with Paget
disease of the bone. However, the majority of osteosarcoma
cases occur in the absence of these risk factors. Numerous
studies of growth and other genetic risk factors have been
conducted but strong data on risk for apparently sporadic
osteosarcoma are limited. The primary goal of this paper
is to examine the recent studies seeking to understand
osteosarcoma etiology through epidemiology and studies of
germline genetics (Figure 1).
2.Osteosarcoma Epidemiology
2.1. Incidence. Osteosarcoma represents approximately 55%
ofchildand adolescentmalignantbonetumorsintheUS[1].
I ti sr a r e l yd i a g n o s e db e f o r et h ea g eo fﬁ v e ,b u tt h ei n c i d e n c e
increases with age until around puberty [1, 3–7]. This pri-
mary peak is followed by a decrease and plateau in incidence
in individuals between 25 and 60 years of age (Figure 2).
A second, smaller peak is observed during the seventh and
eighthdecadesoflife;thisbimodalageincidencedistribution
ofosteosarcoma isobservedworldwide [8].This isalso noted
in childhood and adolescent osteosarcoma where rates are
relatively consistent around the world, ranging between 3
to 4.5 cases/millionpopulation/year [6, 8–13]. The rates in
older persons have been less studied; current estimates are 1
to 2cases/millionpopulation/year for persons aged 25 to 59
yearsand1.5to4.5cases/millionpopulation/yearforpersons
over the age of 60 [1, 8]. Elderly individuals have a higher
incidence of osteosarcoma related to Paget disease of the
bone or as a consequence of treatment for a diﬀerent cancer
[1, 6, 14–16]. In the US and Europe, osteosarcoma incidence
has somewhat increased over time in younger cases [1, 6, 12]
and decreased in elderly individuals in the US [1].
In the US, using population data from the Surveil-
lance, Epidemiology, and End Results (SEER) program,
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Figure 1: Potential contributing factors in the etiology of osteosarcoma.
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Figure 2: Incidence of osteosarcoma per million population. Data were derived from the Surveillance, Epidemiology, and End Results (SEER)
program on the US population. Previously published by Mirabello et al. [2].
on the age of onset [17]: (1) in children and adolescents,
the incidence is greatest in Asian/Paciﬁc Islanders; (2) in
individuals 25–59years of age, the incidence is greatest in
Blacks; (3) in individuals over the age of 60, osteosarcoma
i n c i d e n c ei sg r e a t e s ti nW h i t e s[ 1]. A higher incidence of
childhood osteosarcoma has been reported in Italy [18],
Latin America [8] ,a n di nt w oA f r i c a nc o u n t r i e s ,S u d a na n d
Uganda [13] compared to other populations around the
world. Lower rates have been reported in Western Australia
compared to the US [19]. Higher rates of osteosarcoma
in the elderly have been noted in the UK and Australia
[8].
It has been reported that, when a wide range of ages
are combined, males are aﬀected with osteosarcoma more
frequently than females [1, 3, 4, 6, 8, 12, 19–21]. However,
ithas also been reported that females less than 15years ofage
have slightly higher rates than males in the same age group
[1, 5, 6, 14, 22–26]. In elderly patients, osteosarcoma is more
common in Blacks [5] and in females, particularly those
with a prior history of cancer [1]. In adolescence, incidence
peaks at a later age and reaches higher rates in males (age
15–19,peakrateof9–15cases/millionpopulation)compared
to females (age 10–14, peak rate of 6–10cases/million
population) [1, 6, 8], which suggests that bone growth,
hormonal changes, and/or development associated with
puberty may be involved in osteosarcoma etiology. This
relationship between osteosarcoma, hormones, and growth
may also partly explain the slightly higher overall incidence
in males compared to females.
2.2. Tumor Location. Osteosarcoma occurs most frequently
in the lower long bones [1, 5, 7, 21]( Figure 3). In young
patients, it most often arises at sites of rapid bone growth,Sarcoma 3
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Figure 3: Five-year relative survival rates (RS) by anatomic site (AS) for individuals with osteosarcoma age 0–25 years and 60+ years in the US.
T h ep e r c e n t( % )o fA Si st h e%o fp a t i e n t si nt h a ta g eg r o u pw i t ho s t e o s a rcoma at that location. This ﬁgure was created using data from the
SEER program in Mirabello et al. [2].
the metaphyses of long bones, such as the distal femur,
proximal tibia, and proximal humerus [1, 21, 27]. The
occurrence ofosteosarcoma most frequently in the metaphy-
seal area adjacent to the growth plate of long bones [28],
which are the sites of particularly rapid growth during the
adolescent growth spurt, reinforces the relationship between
bone growth and osteosarcoma formation. There may be an
increased vulnerability at these physes due to the high cell
turnover during puberty. The tendency of osteosarcoma to
occur in the extremity bones decreases with age, although
themost common site isstill thelowerlong bones. The lower
long bones account for approximately 80% of osteosarcoma
in the young patients, 27–43% in middle aged and elderly
persons[1,3,16,29].Inelderlypatients,osteosarcomasoften
occur secondary to Paget’s disease of the bone or some other
benign bone lesion [14–16].
The anatomic site distributions do not vary signiﬁcantly
by sex or race in young patients [1]b u tt h e r ei sm o r e
variability in middle-aged and elderly patients. This includes
ahigherfrequencyofosteosarcoma ofthemandibleinBlacks
compared to Whites, and higher frequency of chest and
upper long bone osteosarcoma but lower rates of vertebral,
pelvic, or mandibular osteosarcoma in females compared to
males [1].
2.3.Survival. Survivalratesvarybyage,gender,diseasestage,
and anatomic site (Figure 3). For children and adolescents,
these rates are similar in most countries, ranging from 55–
75%; although, lower rates (19–39%) have been observed
in Slovakia, Estonia, and Denmark [1, 8, 30–33]. The ﬁve-
year survival rate in persons aged 0–39 years was 58% in
northernEngland [12]and 53%in Great Britain[26]. The 5-
year survival in Finland for the whole study population was
58% [34]. Survival at 5years was 57% for patients of all ages,
68% for those <41years, and 22% for patients older than
65years at an institute in Italy [35, 36] .D a t af o rp a t i e n t so f
all ages from the US National Cancer Database reported a 5-
year survival of 53.9% [21], similar to the 54% reported for
all age cases at the M.D. Anderson Cancer Center [37]. SEER4 Sarcoma
data in the US from 1973 to 2004 showed that the relative 5-
year survival rate for young-onset osteosarcoma was 61.6%;
it was 58.7% for middle aged persons and 24.2% for persons
over 60years of age [1]. This paper showed a sharp decrease
in survival after age 50, with rates dropping from around
50% for patients in their 50s to 17% for those in their mid-
late 60s to only 11% for those in their 80s. Others have also
shown thatsurvival ratesin adultsoverage40years are lower
than in younger patients with rates ranging from 18–55%
[16, 21, 29, 36–39].
Females have higher survival rates than males [1, 12, 21,
26, 32, 33, 40]. Disease stage is an important prognostic
factor in patients with osteosarcoma at all ages, with distant
d i s e a s eh a v i n gam u c hl o w e r5 - y e a rs u r v i v a lr a t et h a n
localized or regional disease [1, 32]. Osteosarcoma survival
rates are higher when it occurs in the short bones, and the
poorest with osteosarcoma of the pelvic region and vertebral
column for all ages [1, 3]. Osteosarcoma pathology has also
been suggested to aﬀect survival, though this is diﬃcult
to evaluate in most reports because many of the subtypes
consist of very small sample sizes and rates are thus unstable.
However, parosteal osteosarcoma has been associated with
ah i g hs u r v i v a lr a t e[ 21], and osteosarcoma with Paget
disease a low rate [1, 21]. It has also been shown that
patientswithlargertumorsize, metastatic disease, soft-tissue
extension of the primary tumor, less tumor necrosis after
neoadjuvant chemotherapy, inadequate surgical margins,
or recurrence have signiﬁcantly worse prognosis [7, 36–
38].
Older patients may have unique tumor biology, for
example, more axial tumors or other factors associated
with a poorer prognosis, such as Paget disease (see below)
and response to therapy due to age-related adjustments in
therapeutic regimens, which could contribute to their worse
overall survival [7, 29, 37]. Overall, osteosarcoma survival
has improved over time with each decade until the 1990s,
but little thereafter [1, 6, 26, 31, 32, 34, 40–43]. It has likely
improved with advancements in patient care and the advent
of chemotherapy, but there is still a need for novel treatment
and patient management strategies shown by the lack of
improvement in the last decade.
3.EnvironmentalExposuresand Osteosarcoma
Studies of environmental exposures and rare cancers, such
as osteosarcoma, are challenging and often limited by
sample sizes. Most studies are case-control, ecologic, and/or
descriptive in nature. This is because the extremely large
cohorts required to study these cancers are nearly impos-
sible to conduct. For example, even in a cohort of one
million individuals, only 4 or 5 would be expected to
develop osteosarcoma. Studies of environmental exposures
and osteosarcoma are often combined with studies of other
bone tumors, including Ewing sarcoma and others. This
makes separating the potentially etiologic clues even more
challenging.Thereaderisreferredtoarecent,comprehensive
review of these studies [44]. Two well-studied exposures are
described below.
Many years ago, it was hypothesized that ﬂuoride could
contribute to osteosarcoma risk. This was based, in part,
on the fact that it is taken up by and stored in bones
and on in vitro data which suggested that ﬂuoride could
act as a mitogen on osteoblasts [45]. Studies of ﬂuoride
exposure and osteosarcoma risk have not yielded conclusive
results and have generatedsigniﬁcant controversy. The initial
ecologic studies suggested that ﬂuoride could contribute to
bone canceretiology,butsubsequentstudiesdidnotconﬁrm
this ﬁnding (reviewed by Eyre et al., 2009 [44]). A more
recent study did suggest an association between ﬂuoride and
osteosarcoma in males but not in females [46] but caution
was suggested in its interpretation [47].
Therapeuticradiation isa proven risk factor forosteosar-
coma. It was noted to occur more frequently than expected
in survivors of Hodgkin disease who received therapeutic
radiation [48, 49]. Increased incidence of osteosarcoma
was also noted in individuals who received Radium for
ankylosing spondylitis (reviewed in [48]). However, very low
doses of radiation received for medical evaluations, such as
X-rays or CT scans are not associated with osteosarcoma risk
(reviewed in [50]).
4.Growthand Osteosarcoma
Since osteosarcoma occurs most commonly during puberty,
a time of rapid bone growth and remodeling, it is highly
plausiblethatfactorsrelatedtogrowthand developmentplay
aroleinosteosarcoma etiology.Casereportsofosteosarcoma
occurring in individuals with acromegaly, a growth disorder
caused by over production of growth hormone, lent further
support to this hypothesis [51]. Early studies suggested that
individuals who were longer at birth and/or taller than their
peers were at increased risk of osteosarcoma [52–55]. These
associations are further supported by the strong positive
association of sporadic osteosarcoma and height in canines
[56].
Osteosarcoma incidence is highest during puberty when
endogenous sex hormones, growth hormones, and insulin-
like growth factor 1(IGF1) levels are at their highest, so
this biological pathway is likely to play an important role
in osteosarcoma etiology. Insulin-like growth factors (IGFs)
play critical roles in carcinogenesis and circulating levels
are associated with risk of several cancers [57], including
prostate, breast, colorectal, and lung cancer [58]. IGF1 is a
potent mitogen for human osteosarcoma cell lines [59, 60].
The overexpression of insulin-like growth factor 2 (IGF2)
a n dl o s so fI G F 2i m p r i n t i n go c c u r si nd i v e r s ec a n c e r s[ 61],
further suggesting a role for this pathway in carcinogenesis.
In addition, one small study identiﬁed single nucleotide
polymorphisms (SNPs) in IGF2R as potential risk factors for
osteosarcoma (see below) [62].
4.1. Height. The association between taller stature and
increased risk of developing osteosarcoma was ﬁrst reported
in 1967 [63]. That study compared the height of 85
individuals with osteosarcoma to 202 controls between 1945
and 1965 and found that the cases were taller than controls.Sarcoma 5
Two subsequent studies of 54 and 18 cases each which used
percentiles of height also noted that the osteosarcoma cases
were taller than expected [54, 64]. Five additional studies
[53, 55,65–67] conﬁrmed the association of increased height
and osteosarcoma risk but eight others [52, 68–74]d i dn o t
ﬁnd an association between height and osteosarcoma risk.
The discrepancies among these studies could be a result of
limited sample sizes, variable methods and control selection
procedures, and thus limited statistical power. However, the
largest study, a cohort study of 962 patients with osteosar-
c o m aw h i c hu s e ds t a n d a r dd e v i a t i o ns c o r e st oe v a l u a t e
the relative height of patients, found that patients with
osteosarcoma were taller than average but the association
was primarily in those less than 18years of age [53].
A recent meta-analysis of height and osteosarcoma
compiled individual osteosarcoma patient data on 1067
osteosarcoma cases derived from 5 published [52, 54, 66, 67,
73] and 2 unpublished studies of height (Mirabello et al.,
Under Review). Cases were compared to age- and gender-
matched 1000 simulated controls per case based on the 2000
US National Center for Health Statistics Growth Charts.
That study showed that “taller-than-average” (51st–89th
percentile)and “verytall”individuals(≥90thpercentile)had
an increased risk of osteosarcoma (odds ratio 1.40, 95%
CI 1.13–1.73, and odds ratio 2.63, 95% CI 1.98–3.49, resp.,
Ptrend < 0.0001).
The meta-analysis (Mirabello et al., Under Review), and
a separate study of 962 patients with osteosarcoma [53],
which was not included in the meta-analysis, conﬁrm that
taller stature is associated with osteosarcoma. However, the
speciﬁc basis for this association is not known. For example,
there are currently no data in the literature on osteosarcoma
and patient height that also consider parental height. The
incidence of osteosarcoma does not vary widely around the
world but the average adult height varies based on country
of origin [75]. Individuals with a more rapid growth velocity
during puberty could potentially have increased risk of
osteosarcoma because celldivisionisoccurring morerapidly.
Attaining a greater height than expected based on parental
heights could also be a risk factor because of the increased
bone growth required. Future studies of parental height
and growth velocity will be helpful in understanding these
diﬀerences.
4.2. Birth Weight. Numerous epidemiologic studies have
evaluatedassociations between high birth weight and cancer.
This is based on the hypothesis that high birth weight may
be the result of multiple factors that are also associated with
cancer.Forexample,IGFsareimportantinfetaldevelopment
[76] and are also associated with cancer risk [57]. Higher
birth weight has been associated with several childhood
cancers, including acute lymphoblastic leukemia (ALL)
[77–79], primary brain tumors [80], rhabdomyosarcoma
[81], and Wilms’ tumor [82, 83]. Interestingly, recent
studies of ALL and Wilms’ tumor suggest that the strongest
associations are in females with high birth weight [82, 84].
Therearealsoseveralstudiessuggestingassociations between
highbirth weightandadult-onsetcancers,includingprostate
and breast cancer [85, 86].
Review of the literature identiﬁed ﬁve published studies
that evaluatedthe potential association between birth weight
and osteosarcoma; four were null [65, 74, 79, 87], and one
showed an association between higher birth weight and
osteosarcoma [52]. The inconsistencies in the published data
on birth weight may also be due to small sample sizes and/or
inconsistent methods. A meta-analysis of the raw data from
two published [52, 79] and one unpublished study of birth
weight and osteosarcoma compared the birth weights of 434
individuals with osteosarcoma to age- and gender-matched
controls (1000 simulated controls per case) derived from
US growth charts (Mirabello et al., Under Review). In that
study, individuals with high birth-weight (≥4046g) had a
marginally signiﬁcant increased risk of osteosarcoma (OR
1.35, 95% CI 1.01–1.79). Females with high birth-weight,
but not males, had an increased risk of OS (OR 1.49, 95%
CI 1.00–2.22). Overall, the association between birth weight
and osteosarcoma is not as strong as the height association,
but it is similar in magnitude to other cancers. It remains
conceivable that prenatal growth and factors that inﬂuence
it, such as growth factors and hormones, contribute to
osteosarcoma risk.
4.3. Paget Disease and Osteosarcoma. Paget disease of bone is
a relatively common metabolic bone disorder that typically
occurs in older individuals [88, 89]. It is characterized by
highly exaggeratedboneremodeling causedbyabnormalities
in osteoclast regulation. Sarcomatous transformation is rare
but associated with a high mortality rate. The incidence
of osteosarcoma secondary to Paget disease is not precisely
known, but studies estimate that about 1% of patients with
Paget disease will develop osteosarcoma [90]. In elderly
persons, about half of the osteosarcomas reported are
estimated to be associated with Paget disease.
The co-occurrence of osteosarcoma in the setting of
abnormal bone remodeling due to Paget disease of the bone
suggests that osteosarcoma may be etiologically related to
abnormal bone remodeling [90, 91]. This could appear to be
the case in elderly individuals but the role of abnormal bone
remodeling in osteosarcoma adolescents is not known. It is
conceivable that a subset of younger patients have increased
genetic risk and that there could be overlap with genes that
contribute to the etiology of Paget disease. Paget disease
is genetically heterogeneous but recent studies implicate
the RANK-NF-κB signaling pathway [89]. Mutations in
SQSTM1, a downstream scaﬀold protein in this pathway,
are associated with familial Paget disease [92]. Many, but
not all, of the associated mutations occur in the ubiquitin-
associated domain of the p62 protein which is encoded by
the SQSTM1 gene [88]. Ubiquitin-associated proteins, such
asp62,are important in theRANK-NF-κBsignaling pathway
which promotes osteoclastogenesis and formation.
5.Genetic RiskFactors
Chromosomal aneuploidy is common in osteosarcoma cells
which suggests that somatic or germline chromosomal
instability could potentially predispose an individual to6 Sarcoma
Table 1: Inherited disorders associated with increased rates of osteosarcoma.
Disorder Gene Chromosome Autosomal
inheritance pattern
Li-Fraumeni Syndrome TP53, tumor protein p53 17p13.1 Dominant
Retinoblastoma RB1, retinoblastoma 1 13q14.2 Dominant
Rothmund ThomsonSyndrome REQL4, RecQ protein-like 4,
DNA helicase 8q24.3 Recessive
Werner Syndrome WRN, Werner syndrome, RecQ
helicase-like 8p12 Recessive
Bloom Syndrome BLM, Bloom syndrome, RecQ
helicase-like 15q26.1 Recessive
Diamond Blackfan Anemia
Ribosomal protein genes,
including RPS19, RPL5, RPL11,
RPL35A, RPS24, RPS17, and
RPS7
multiple Dominant
osteosarcoma [93, 94]. There are numerous studies of the
somaticchangespresentinosteosarcoma cellsbutacommon
somatic defect has not yet been identiﬁed. Osteosarcoma
is associated with several cancer predisposition syndromes
that are caused by highly penetrant germline mutations
as described in Table 1. These disorders are extremely rare
and not a common cause of osteosarcoma. However, they
may provide important insights into osteosarcoma etiology
because the same genes that are associated with these
disorders are often also disrupted in osteosarcoma tissues.
Common germline genetic variants, such as SNPs, are
associated with risk of numerous diseases, including cancer.
The role that they play in sporadic osteosarcoma is not
known, but several pilot studies have sought to understand
this (Table 2).
5.1. Inherited, Cancer-Prone Disorders. Inherited cancer
predisposition syndromes are a heterogeneous group of
disorders. There are several disorders in which higher
rates of osteosarcoma are noted (Table 1). Studies of these
disorders have provided important clues to understanding
osteosarcoma etiology.
The careful characterization of families with high rates
of breast cancer, sarcomas, and other cancers by Li and
Fraumeni Jr. in 1969 led to the recognition of the syndrome
now known as Li-Fraumeni syndrome (LFS) [101, 102].
The classic LFS is clinically diagnosed based on family
history which includes a personal history of a sarcoma
diagnosed under the age of 45, a ﬁrst-degree relative with
cancer under age 45, and another ﬁrst- or second-degree
relative with cancer diagnosed under age 45 or sarcoma at
any age. LFS is caused by autosomal dominant germline
mutations in TP53 [102, 103] although approximately 30%
of individuals who meet clinical criteria for LFS do not
have a TP53 mutation. Additional clinical descriptions and
criteria for mutation testing in individuals with suspected
LFS are reviewed in [102]. The p53 protein, encoded by
TP53,i sc r u c i a lf o rn o r m a lc e l lg r o w t h ,a p o p t o s i s ,D N A
repair, and numerous other cellular processes. The p53 gene
is mutated in a majority of somatic tumor tissues, many
of which disrupt the DNA-binding domain and result in
a loss of tumor suppressor function [104]. Many, but not
all, osteosarcomas have TP53 mutations but these have not
consistently been correlated with disease stage or prognosis
[105].
Retinoblastoma is a malignant retinal tumor that typ-
ically occurs prior to the age of 5. It is caused by muta-
tions in the RB1 tumor suppressor gene [106]. The RB1
gene encodes the Rb protein which is critical in normal
cell cycle and diﬀerentiation processes. Loss of normal
Rb function is noted in several sporadic human tumors,
including apparently sporadic osteosarcoma. In addition,
osteosarcoma is the most common second tumor in patients
withretinoblastoma.Itoccursmorefrequentlythanexpected
in individuals with RB1 mutations whether or not they had
radiation therapy [107, 108]. The standardized incidence
ratio (SIR) for osteosarcoma occurring after retinoblastoma
was 406-fold over expected for individuals who had radi-
ation and 69-fold over expected for those who had not
received radiation therapy. This suggests that both primary
genetic and gene/environment interactions contribute to
osteosarcoma development in the setting of a germline RB1
mutation, and this may also be the case in apparently
sporadic osteosarcoma.
Increased rates of osteosarcoma are also present in
individuals with germline mutations in DNA helicase genes,
including Rothmund Thomas syndrome (RTS), Werner
syndrome, and Bloom syndrome. RTS is a rare, autosomal
recessive disorder caused by mutations in the DNA helicase
RECQL4 (reviewed in [109, 110]). It has a characteristic
sun-sensitive rash which presents in infancy and then enters
a chronic phase with poikiloderma through adulthood.
Individuals with RTS may also have small stature, skeletal
dysplasias, sparsehair, orcataracts.Osteosarcoma isthemost
common cancer in RTS; one study of 41 patients found
that 32% had osteosarcoma [111]. The role of RECQL4 in
sporadic osteosarcoma is not well understood. Since the
DNA helicases are critical for normal DNA structure and
f u n c t i o n ,i ti sf e a s i b l et h a tp r o t e i n si nt h i sf a m i l ya r el i k e l yt o
be important in carcinogenic processes and could contribute
to the DNA damage and chromosomal aberrations seen in
osteosarcoma cells.Sarcoma 7
Table 2: Association studies of single nucleotide polymorphisms and osteosarcoma risk. Abbreviations: SNP: single nucleotide
polymorphism; OR: odds ratio; CI: conﬁdence interval.
First Author, Year,
Reference
No.
cases/no.
controls
Study Design Gene Main Finding(s)
Pati˜ no-Garcia, 2000,
[95] 63/111 Case-Control Tumor Necrosis Factor-α
(TNF)
Evaluated 3 SNPs in the promoter. TNF-α -238G>A
was inversely associated with risk (OR 0.17, 95% CI
0.04–0.76, P = 0.0095)
Ruza, 2003, [66] 72/143 Case-Control
Vitamin D Receptor (VDR)
3 SNPs (FokI, ApaI, TaqI) studied. FokI Ff genotype
associated with increased risk (OR 1.78, 95% CI 1.0–
3.16, P = 0.048)
Estrogen Receptor (ESR1) 2 variants (Pvu II and XbaI) evaluated were not
associated with osteosarcoma
Collagen 1α1( COL1A1) 1 variant studied (Msc 1) was not associated with
osteosarcoma.
Savage, 2007, [96] 104/74 Hospital-based
Case-Control Tumor Protein p53 (TP53)
12 tag-SNPs in TP53 genotyped. Recessive model
noted potential increased risk with rs1642785
(IVS+38C>G; OR 6.7, 95% CI 1.06-41.6, P = 0.04)
andrs1042522(Ex4+119C>G, P72R; OR7.5, 95%CI
1.2–46.3, P = 0.03).
Savage, 2007, [62] 104/74 Hospital-based
Case-Control
Insulin-like Growth Factor
2 Receptor (IGF2R)
E v a l u a t e d5 2S N P si n1 3g r o w t h - r e l a t e dg e n e s .T w o
linked IGF2R SNPs, rs998075 (Ex16+88G>A) and
rs998074 (IVS16+15C>T), associated with increased
risk (haplotype OR 2.04, 95% CI 1.29–3.24, P =
0.006).
Koshkina, 2007, [97] 123/510 Case-Control
Fas (TNF receptor
superfamily, member 6;
FAS)
4S N P si nFas studied. Increased risk with exon
3, 18272A>G, most pronounced in non-Hispanic
whites (OR 2.3, 95% CI 1.2–4.6, P = 0.014)
Toﬀoli, 2009, [98] 201/250 Case-Control
Mdm2 p53 binding protein
homolog(MDM2)
1S N Pi nMDM2 studied, rs2279744 (SNP309T>G),
was associated with high-grade osteosarcoma in
females
Tumor Protein p53 (TP53) 1 SNP evaluated, rs1042522 (Ex4+119C>G, P72R),
was associated with survival.
Hu, 2010, [99] 168/168 Case-Control Transforminggrowth factor
beta receptor 1 (TGFBR1)
1 variant evaluated (TGFBR1∗6A) was associated
with increased susceptibility (OR 4.6, 95% CI 2.3–
7.9, P = 0.002)
Mirabello, 2010,
[100] 99/1430 Hospital-based
Case-Control 8q24 region
Evaluated 214 SNPs, including 9 previously asso-
ciated with cancer. Strongest association noted at
rs896324 in additive model (OR 1.75, 95% CI 1.13–
2.69, P = 0.01)
Bloom syndrome, caused by autosomal recessive inher-
itance of mutations in the BLM helicase, also has a charac-
teristic rash, but not true poikiloderma [112]. Individuals
have severe pre- and postnatal growth retardation, learning
disabilities, and high rates of cancers. The most common
cancers are epithelial, hematopoietic, lymphoid, connective
tissue, germ cell, nervous system, and kidney cancers. Three
out of 168 individuals with Bloom syndrome listed in the
Bloom syndrome registry were reported to have a sarcoma
between 1954 and 2000 [112]. While osteosarcoma is still
rare in Bloom syndrome, it is more common in this disorder
than in the general population. The role of BLM mutations
in osteosarcoma somatic cells is not well described.
Werner syndrome is a premature aging syndrome which
typically presents after the ﬁrst decade of life [113, 114]. It is
causedbymutationsintheWRN DNAhelicaseandinherited
in an autosomal recessive manner. Individuals with Werner
syndrome typically have characteristic “bird” facies, short
stature, parental consanguinity, cataracts, atrophic skin, and
signs of premature aging such as atherosclerosis. They are at
increased risk of osteosarcoma as well as other malignancies
[115, 116].
Diamond Blackfan anemia (DBA) is another inherited
disorder associated with increased risk of osteosarcoma
[117]. DBA is an inherited red blood cell aplasia with a
broadphenotypicspectrum.Patientshavevariabledegreesof
anemia, normal leukocytes and platelets, occasional physical
malformations, and increased risk of acute myelogenous
leukemia, myelodysplastic syndrome, and solid tumors.
Approximately40%ofpatientshavean identiﬁablemutation
in a gene important in ribosomal function (RPS19, RPL5,
RPL11, RPL35A, RPS24, RPS17, or RPS7). Osteosarcoma
was noted in three of the 354 patients in the DBA registry
in 2001 [118]. The role of these ribosomal proteins in8 Sarcoma
osteosarcoma biology is unexplored. However, the higher
than expected occurrence of osteosarcoma in patients with
DBA is notable and warrants further study of ribosomal
function in osteosarcoma.
5.2. Inherited, Cancer-Prone Disorders. The inherited disor-
ders caused by rare, highly-penetrant mutations and associ-
ated with osteosarcoma described above explain only a very
small percentage of all osteosarcoma cases. It occurs more
often in individuals without a family history of cancer or
othermedicalproblems.Severalstudieshavebeenconducted
in an eﬀort to understand the contribution of common
geneticvariants, such as SNPs,toosteosarcoma risk (Table 2)
although the vast majority await replication. SNPs are the
most common form of genetic variation in the genome;
approximately 10 million with minor allele frequencies of
at least 1% are thought to be present in the genome. Most
SNPs do not alter gene expression or protein function, but
a subset can have subtle, yet important, biological eﬀects.
For example, an SNP in the promoter of the MDM2 gene
increases the aﬃnity of the Sp1transcription factor which
results in higher MDM2 levels and p53 pathway attenuation
[119].
Most ofthe studies ofSNPs and osteosarcoma conducted
to date have been limited by sample size and therefore
should be considered exploratory in nature (Table 2). These
studies were based on ap r i o r ihypotheses that the genes
of interest were potentially important in osteosarcoma
biology. The ﬁrst such study evaluated three SNPs in the
promoter of the Tumor Necrosis Factor-α (TNF)g e n ei n
63 osteosarcoma cases and 111 controls from Spain [120].
The TNF protein is a proinﬂammatory cytokine that has
important roles in cellular proliferation and diﬀerentiation.
It is also involved in bone remodeling and is a component
of the RNKL pathway described above. SNPs in the TNF
promoter have also been noted to aﬀect protein expression.
That study suggested that the TNF-238G>Aw a si n v e r s e l y
associatedwithosteosarcoma.TheTNF-308G>Avariantwas
notassociatedwithosteosarcoma.Theauthorsalsoevaluated
these genotypes in 47 individuals with Ewing sarcoma but
d i dn o tﬁ n da na s s o c i a t i o n .
In a second study, the same group hypothesized that
variants in the estrogen receptor (ESR1), vitamin D recep-
tor (VDR), and/or collagen 1α1( COL1A1) gene could
be osteosarcoma risk factors. Variants in ESR1 could be
important in osteosarcoma since estrogen is critical during
puberty which is the key time of risk for osteosarcoma.
The VDR and COL1A1 genes are required for proper bone
formation and thus, if aberrations are present, could be
associated with osteosarcoma. A total of 72 osteosarcoma
cases and 143 controls were evaluated. Ruza et al. found that
the Ff genotype ofVDR was associated with increased risk of
osteosarcoma(oddsratio[OR]1.78,95%conﬁdenceinterval
[CI] 1.0–3.16, P = 0.048) [66]. Variants in ESR1 or COL1A1
were not associated with osteosarcoma.
Since mutations in TP53 cause LFS and osteosarcoma
is a deﬁning tumor of the syndrome, SNPs in TP53 were
evaluated as potential osteosarcoma risk factors in the Bone
Disease and Injury Study of Osteosarcoma (BDISO), a
hospital-based study of 104 cases and 74 controls [96]. Sub-
jects genotyped were whites from the US Twelve tag-SNPs
were genotyped and several inheritance models evaluated.
The recessive inheritance model suggested that rs1642785
(IVS+38C>G) and rs1042522 (Ex4+119C>G, Pro72Arg)
were associated with osteosarcoma risk. However, these
genotypeswere quiterare and this study, likethose described
above, was limited by its small sample size.
In a diﬀerent study of the p53 pathway, Toﬀoli et al.
genotyped the Pro72Arg (rs1042522, Ex4+119C>G) SNP in
TP53 and the MDM2 -309 promoter SNP (rs2279744, T>G)
in 201 osteosarcoma cases and 250 controls from Italy [98].
The Pro72Arg SNP in TP53 has been associated with risk of
several cancers, including lung and breast cancer (reviewed
in [121]). In addition, the presence of the 72Arg allele was
correlated with earlier age ofcanceronset inindividuals with
LFS [122]. The MDM2 protein is an important regulator of
TP53 function, and the -309 T>G SNP is associated with
altered MDM2 expression. LFS patients with the G allele
have an earlier age of onset of cancer [122]. In addition, this
MDM2 SNP is also associated with risk of several cancers
[121]. This osteosarcoma study noted that the MDM2-
309 SNP was only associated with high-grade osteosarcoma
in females. The TP53 Pro72Arg SNP was not associated
with osteosarcoma risk but an association with survival was
suggested. This study did not report results of a recessive
genetic model so direct comparison with the BDISO TP53
ﬁndings in osteosarcoma was not possible.
The ﬁrst study to evaluate SNPs in growth-related genes
did so based on the hypothesis that since osteosarcoma
most commonly occurs during a period of active growth,
that variants in genes that regulate pubertal growth could
be important osteosarcoma risk factors. Common SNPs in
13 growth-related genes were also evaluated as candidate
risk modiﬁers in the BDISO. Of the 52 SNPs evaluated,
two correlated SNPs in insulin-like growth factor receptor
2( IGF2R, rs998075 and rs998074) were associated with
increased risk of osteosarcoma (OR 2.04, 95% CI 1.29–3.24)
[62]. One of those SNPs, rs998075 (Ex16+88G>A), resulted
in loss of methylation in a CpG island but the impact of this
alteration onIGF2R proteinfunction is not known. As noted
above, the IGFs are potential regulators of carcinogenesis in
several cancer types and IGF1 levels have been associated
with cancer risk. Followup of these ﬁndings in osteosarcoma
is needed to better understand how genetic variation in
IGF2R contributes to its etiology.
SNPsinthe8q24chromosomalregionarebeingintensely
studied because genome-wide association studies (GWAS)
have consistently found them to be associated with risk of
adult onset cancers, including prostate, breast, colon, and
others [123–125]. Therefore, we recently evaluated 214 SNPs
in 8q24 with a focus on the 9 SNPs which were previously
associated with cancer in GWAS [100]. Ninety-nine cases
and 65 controls plus an additional 1365 controls from the
Prostate,Lung,Colorectal,Ovarian (PLCO)cancerscreening
trial were genotyped. All subjects were self-identiﬁed whites.
Associations with the 9 SNPs previously associated with
cancer were not noted in this study. Overall, seven SNPsSarcoma 9
were associated with osteosarcoma; the strongest result was
noted for SNP, rs896324 (OR 1.75, 95% CI 1.13–2.69).
These SNPs are in slightly diﬀerent locations than the
S N P sa s s o c i a t e dw i t ho t h e rc a n c e r s .T h ed e t a i l so f8 q 2 4
are still being explored, but a long-range regulator of the
MYC proto-oncogene may be present in this region [126].
MYC inhibition was suggested to cause diﬀerentiation of
osteosarcoma cells into mature osteocytes in a mouse model
[127]. The combination of these ﬁndings suggests that
further study of the 8q24 locus may yield important insights
into the regulation of MYC and its role in osteosarcoma
pathogenesis.
The Fas protein (gene name FAS,o rTNFRSF6)i sa
member of the TNF receptor superfamily and plays a central
role in programmed cell death. Genetic variants in FAS have
been associated with increased risk of several cancers, such
as melanoma, gastric, and renal cell cancer [128, 129]. Based
on this, Koshkina et al. hypothesized that SNPs in FAS may
be osteosarcoma risk factors. They evaluated four SNPs in
FAS in 123 osteosarcoma cases and 510 controls from the US
[97]. An important limitation of this study is the fact that the
study subjects were of variable ethnicity; 51.2% of cases (63)
and 78% of controls (398) were described as non-Hispanic
whites. An SNP in exon 3 (18272A>G, dbSNP number not
given) was associated with increased risk of osteosarcoma in
non-Hispanic whites (OR 2.3, 95% CI 1.2–4.6).
TGF-β signaling is important in the regulation ofcellular
proliferation. A functional polymorphisms, referred to as
TGFBR1∗6A, is caused by the deletion of 3 GCG triplets
which code for alanine in exon 1. It is a hypomorphic variant
that results in reduced TGF-β growth inhibitory signaling.
The TGFBR1∗6Avariant has beenassociated with breast and
ovarian cancer, but not consistently associated with other
cancer types [130]. Thus, the potential role of this variant
wasexploredina studyof168osteosarcoma patientsand 168
controls [99]. The authors found that both homozygosity
and heterozygosity for the TGFBR1∗6A variant resulted in
increased risk of osteosarcoma in the Chinese population, in
a gene-dose response pattern (OR 4.6, 95% CI 2.2–7.97 and
OR 2.9, 95% CI 1.59–5.34, resp.).
As a whole, the studies conducted, to date, of common
genetic variants and osteosarcoma risk have yielded promis-
ing results. Their strength lies in the fact that they have
evaluated genes which have a high biologic likelihood of
being related to osteosarcoma etiology based on laboratory
and/or other epidemiologic studies. However, the results of
all the studies described above and in Table 2 should be
interpreted with caution because they all have small sample
sizes and limited statistical power. Future, large, multi-
institutional, collaborative studies are required to obtain the
necessary samplesize andadequatestatisticalpowertofollow
up these ﬁndings.
6.Summaryand FutureDirections
Some progress has been made in understanding the cause of
o s t e o s a r c o m a ,b u tw es t i l lh a v em u c ht ol e a r n .T h eb i g g e s t
clue generated in the study of osteosarcoma epidemiology
is its association with either rapid or abnormal growth. Its
occurrence primarily during the adolescent growth spurt
and association with tall height at diagnosis show that
bone growth is clearly an important factor. It is not known
whether or not tall stature, in and of itself, is the key,
or if it is taller stature than expected based on parental
heights or due to height velocityduring puberty. An ongoing
Children’s Oncology Group epidemiology study which will
investigate parental height and growth charts of children and
adolescents with osteosarcoma will help shed light on this
question. Future clinical and laboratory studies should also
carefully evaluate the complex hormonal changes that occur
before, during, and after puberty.
The association of osteosarcoma with the abnormal bone
remodeling present in Paget disease also warrants more
careful examination. The role of variants in genes of the
RANKL-NF-κBsignaling pathway,which are strongly associ-
ated with Paget disease, have not been thoroughly studied as
potential osteosarcoma risk factors. The case reports of the
occurrence of osteosarcoma in the setting of acromegaly, a
state of abnormal growth hormone production, also warrant
followup. Is the literature biased by these case reports, or is
there an increased risk of osteosarcoma amongst individuals
with acromegaly?
The studies of rare, but highly penetrant, cancer predis-
position syndromes can shed some light on the biological
mechanisms of osteosarcoma. In general, the cancers that
occur in individuals with the cancer predisposition syn-
dromes described above occur at much younger ages than
in the same cancer types in the general population. The
fact that several of these syndromes include osteosarcoma
in the phenotype suggests that there may be common
genetic mechanisms which also contribute to the apparently
sporadic occurrence of osteosarcoma. It is also likely that
the genetic contribution to cancers which occur in the
ﬁrst two decades of life, such as osteosarcoma, is greater
than in cancers which do not occur until many decades
later. In childhood cancer, there has been considerably less
time for exposure to known and unknown environmental
carcinogens.
The contribution of environmental exposures to
osteosarcoma and to other cancers of children and young
adults is not known. The heterogeneity and relative rarity
of these cancers create signiﬁcant complexity in study
design and interpretation. In addition, it is likely that
a combination of environmental exposure and genetic
risk factors contribute to cancer risk. Large, longitudinal,
cohort studies of the cancers of children and young adults
are required to address these study design issues and
likely contribution of multiple factors. The International
Childhood Cancer Cohort Consortium (I4C) is a multi-
institutional, international collaborative group of childhood
cohort studies that is working to better understand the
etiology of childhood cancer [131]. However, even this
large-scale eﬀort will not be able to address osteosarcoma
risk factors in detail, because of its rarity.
Like many cancers, the etiology of most osteosarcoma
remains unknown. Epidemiology studies have provided
many important clues, such as associations with puberty,10 Sarcoma
height, and disorders of bone growth and remodeling. The
genetic clues derived from the occurrence of osteosarcoma
in the setting of germline mutations in genes such as TP53
and RB1 suggest that the genetic contribution to what
appears to be sporadic osteosarcoma may also be important.
Understanding potential environmental contributions to
osteosarcoma riskisverychallengingbecauseofitsrarityand
the fact that a single environmental exposure is not likely
to be the primary cause. Numerous studies are underway
which seek to improve our understanding of osteosar-
coma etiology and through this understanding we will be
better equipped to counsel patients and reﬁne treatment
strategies.
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